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comparison groups strengthen the robustness of the findings and 
indicate a similar disease burden of OA and RA. 
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Aim of study: As calcitonin (CT) reduces the severity of cartilage 
lesions and prevents the net loss of collagen, hyaluronan and ag- 
grecan aggregates from the cartilage tissue in canine experimen- 
tal osteoarthritis (OA), this preliminary, randomized, double blind, 
placebo controlled, parallel study was conducted for 3 months to 
assess the efficacy of a novel oral formulation of CT in patients 
suffering from knee OA. 
Methods: For up to 84 days, patients received daily either a 
placebo (n=16), 0.5 mg CT (n=17) or 1 mg CT (n=18). Clin- 
ical efficacy on pain, function and stiffness was evaluated by 
Lequesne's algofunctional indices (LI). Biochemical parameters 
of joint metabolism, as assessed by enzyme immunoassays, in- 
cluded urinary levels of type I and type II collagen C telopeptide 
(CTX-I and CTX-II, respectively) as well as serum levels of type 
II collagen neoepitope C2C, matrix metalloproteinase (MMP)- 
3, collagenase-3 (MMP-13), tissue inhibitors 1 and 2 of MMPs 
(TIMP-1 and TIMP-2) and hyaluronan (HA). Statistical analysis 
included analysis of variance followed by Tukey test whenever 
needed. 
Results: The number of withdrawals was 2 in the placebo group 
(lack of efficacy), 4 in the 0.5 mg CT group (1 for lack of efficacy 
and 3 for nausea and headache) and 4 in the 1 mg CT group 
(2 for protocol violation and 2 for nausea and headache). In the 
placebo group there was no significant change in the mean 4- SD 
value of LI (from 14.8 4- 2.7 at day 0 to 12 4- 4.3 at day 84). In 
the 2 CT groups, the mean value of LI was similar at day 0 (15.4 
4- 2.6) and was significantly decreased at day 84 (10.6 4- 3.8 in 
the 0.5 mg group and 9.6 4- 3.2 in the 1 mg group). Further, when 
compared to values at study entry, levels of biochemical parame- 
ters had changed significantly in all groups at day 84 (p < 0.05 to 
0.01). In the placebo group, there was a significant increase in the 
mean urinary levels of both CTX-1 (15%) and CTX-II (9%) and in 
the mean serum levels of C2C (29%), MMP-13 (153%), MMP-3 
(49%), and HA (25%). In contrast in the 1 mg CT group, there was 
a significant decrease in the mean urinary levels of both CTX-1 
(10%), CTX-II (21%) as well as in the mean serum levels of C2C 
(25%), MMP-13 (40%), MMP-3 (18%) and HA (28%). Results ob- 
tained in the 0.5 mg CT group were intermediate between the 2 
other groups and are not reported. No change in the mean serum 
levels of TIMP-1 and TIMP-2 was observed in the 3 groups. 
Conclusions: Although the cohort of patients was rather small, 
results of this preliminary study strongly suggest that CT exhibits 
not only clinical efficacy but also reduces markedly the levels 
of several biochemical parameters of joint metabolism which all 
have been shown to have a pejorative prognostic value of the OA 
disease process in longitudinal studies including large cohorts of 
patients. 
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Aim of Study: To confirm the positive effects of Pulsed Signal 
Therapy (PST) for the treatment of osteoarthritis - a prospec- 
tive, double-blind, randomized study in patients with gonarthrosis 
stages I-III, as classified by Altman et aL, and severity as classi- 
fied by Brandt etaL 
Method: 2 Groups: 
• PST-treated group and placebo group. 
• Each patient was randomized into either the placebo or treat- 
ment group using envelopes, each containing 4 identical smart 
cards (chipcards). The only distinction between the cards was 
the serial number. Two were active and two placebo. 
Treatment: A pulsed signal carried on an electromagnetic wave is 
delivered from a medical device, to target the affected tissue by 
direct induction. PST-technology utilizes direct current and pro- 
duces a quasi-rectangular waveform with a field strength of 12.5 
G and a frequency of 1-30 Hz. The frequency is pulse modulated 
and implementation is by a free-wheeling diode. The generated 
pulsed signal, of specific energy parameters, stimulates the re- 
pair and restoration of damaged cartilage tissue, and accelerates 
healing, by mimicking the innate streaming potential(s) generated 
during mechanical compression. 
Treatments were administered aily for one-hour, over nine con- 
secutive days, with allowed interruption over the weekend. A 
10cm visual analog scale (VAS) was used to evaluate patients 
before PST treatment (baseline), and at 1-month, 3-months and 
6-months post-treatment. 
Statistical method: The paired T test was used to analyze the 
difference in the mean VAS score at 1-month, 3-months and 6- 
months, compared to baseline. Significant esting was two tailed, 
with p<0.05 accepted as statistically significant. 
Results: 41 patients were randomly recruited into the study - 21 
into the placebo group and 20 into the active group. There were 
no patients lost in the follow-up periods nor were any withdrawn 
from the study. The two groups did not differ significantly with re- 
spect to age, sex, race, body weight or duration of symptoms. 
There were no adverse effects reported by any patients. There 
were no patients who reported using more than their usual medi- 
cation or requiring new medications for their knee pain during the 
study period. 
The mean baseline VAS score of the two groups was not sta- 
tistically different (p=0.82). In the active group, the improvement 
in the VAS score at 1-month, 3-months and 6-months when 
compared to the baseline VAS score was statistically significant 
(p<0.05). The placebo group, however, did not show any statisti- 
cal significance (p>0.05). 
Conclusion: With over 25 clinical studies supported by in vitro 
studies, this prospective double-blind randomized study confirms 
the efficacy of PST for the treatment of osteoarthritis. PST stimu- 
lates the repair and restoration of damaged cartilage tissue, and 
accelerates the healing process. To date, no adverse effects have 
been reported. 
In this study, patients with early gonarthrosis demonstrated a sta- 
tistically significant reduction in pain as measured by VAS, post 
PST-treatment. Pain reduction begins as early as one month and 
lasts for as long as 6 months after treatment. 
